Ropes & Gray advised Pfizer Inc. in its minority equity interest in Dutch biopharmaceutical company AM-Pharma B.V. and an exclusive option to acquire the remaining equity in the company. The option becomes exercisable based on completion of a Phase II trial – expected in the second half of 2016 – of recombinant human alkaline phosphatase (recAP) in the treatment of acute kidney injury (AKI) related to sepsis. Pfizer paid $87.5 million for the minority equity interest and exclusive option, with additional potential payments of up to $512.5 million upon option exercise and potential launch of any product that may result from the agreement. Other terms of the transaction, announced May 11, were not disclosed.
The Ropes & Gray team was led by mergers & acquisitions partner Christopher Comeau (Boston) and included life sciences partner Albert Cacozza (Washington, D.C.); tax partner David Saltzman (Boston); and securities & public companies associate Sarah Davis (Boston).
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.